Results 221 to 230 of about 104,915 (286)

Safety of 8‐Week Administration With Ashwagandha (Withania somnifera) Root Extract in Adults With Stress and Anxiety: Findings From a Prospective, Randomized, Multi‐Center, Double‐Blinded, Placebo‐Controlled Study

Phytotherapy Research, EarlyView.
ABSTRACT Ashwagandha (Withania somnifera) has been recognized for enhancing physical strength, mental well‐being, and overall vitality. Despite its long‐standing use across generations, some clinical reports have noted occasional adverse events. This study compared the safety and tolerability of Ashwagandha Root Extract (ARE) in healthy adults.
Ketan Pakhale, Jaising Salve, John Ademola, Jose Parraca, Deepak Langade   +4 more
wiley   +1 more source

Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation? [PDF]

Clin Transl Sci, 2015
Holbein ME, Berglund JP, Weatherwax K, Gerber DE, Adamo JE.   +4 more
europepmc   +1 more source

Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities. [PDF]

Soc Sci Med, 2015
Fisher JA, Cottingham MD, Kalbaugh CA.
europepmc   +1 more source

Staging concept for aging management: Definition, mechanism, and coping strategies

VIEW, EarlyView.
We divided the overall aging stage into “pre‐aging”, “aging compensation”, and “aging disability”. For each stage, we delineate the clinical presentations, biological phenomena, theoretical underpinnings, and key management priorities. Abstract Aging, as a gradual and largely irreversible biological process, characterized by declining organismal ...
Zhonghan Wang, Shixian Liu, Shangyu Du, Xiangran Cui, Bo Chao, Minglei Liu, Minfei Wu   +6 more
wiley   +1 more source

Experiences of Women and Clinicians During the Introduction of Uterine Transplantation to the UK: A Qualitative Case Study

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To explore the experiences of women and clinicians during the introduction of uterine transplantation (UTx) to the UK. Design A qualitative study utilising prospective case study methodology (interviews and observations) over 6 years.
Daisy Elliott, Richard J. Smith, Maeve Coyle, Rhiannon Macefield, Saliha Vali, Anni King, Natalie Blencowe, Cynthia Ochieng, Christin Hoffmann, Isabel Quiroga, Ben P. Jones, Ariadne L'Heveder, Kerry N. L. Avery, Jane M. Blazeby   +13 more
wiley   +1 more source

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction, EarlyView.
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study.
Elizabeth Knock, Krista J. Siefried, Gill Bedi, Steven Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett   +8 more
wiley   +1 more source

Varenicline for cannabis use disorder: A randomized controlled trial

Addiction, EarlyView.
Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD ...
Aimee L. McRae‐Clark, Kevin M. Gray, Nathaniel L. Baker, Brian J. Sherman, Bryan Tolliver, Jessica Burt, Alonzo Steplight, Elizabeth Chapman, Amanda Wagner   +8 more
wiley   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Law and Health Care Newsletter, vol. 24, no. 1, Fall 2016 [PDF]

, 2016

core   +1 more source

A One‐Strength Dose Escalation Regimen for Birch Pollen SCIT Is Safe and Tolerable in Children, Adolescents, and Adults

Allergy, EarlyView.
This study evaluated safety and tolerability of birch pollen SCIT during dose escalation with a new One‐Strength regimen (3 injections, Strength B) compared to the Standard regimen (7 injections, Strengths A and B) in patients aged 5–65 years. Safety and tolerability were comparable between the two regimens in adults, adolescents, and adolescents, as ...
Marek Jutel, Ludger Klimek, Michael Gerstlauer, Dana Troyke, Kristina Duwensee, Christian Vogelberg   +5 more
wiley   +1 more source